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A B S T R A C T
Influenza A virus (IAV) and influenza B virus (IBV) cause substantial morbidity and mortality during seasonal
epidemics. On basis of variation in the surface glycoprotein hemagglutinin, two antigenically distinct lineages of
IBV are distinguished: B/Victoria/2/87-like (B/Vic) and B/Yamagata/16/88-like (B/Yam). To prevent IAV and
IBV infections, both trivalent (containing IBV of one lineage) and quadrivalent (containing IBV of both lineages)
influenza vaccines are used. In addition to virus-neutralizing antibodies, inactivated influenza vaccines induce
antibodies that mediate antibody-dependent cellular cytotoxicity (ADCC). Here, we determine whether vacci-
nation with trivalent or quadrivalent inactivated influenza vaccine induces ADCC mediating antibodies directed
to IBV of the two different lineages, and whether these antibodies cross-react with IBV of the opposing lineage. A
robust ADCC assay based on the use of recombinant hemagglutinin and a continuous natural killer cell line that
expresses FcγRIII (CD16) was used to detect the presence of ADCC mediating antibodies. Paired pre- and post-
vaccination serum samples from 26 and 15 study subjects that received a trivalent or quadrivalent inactivated
influenza vaccine, respectively, were assessed for the presence of ADCC mediating antibodies specific for HA
derived from viruses of the B/Vic or B/Yam-lineage. Furthermore, the relative contribution of HA1- and HA2-
subunit-specific antibodies to the ADCC response was determined. We found that seasonal inactivated influenza
vaccines induce HA-head- and HA-stalk-specific antibodies that mediate ADCC. As expected, the quadrivalent
vaccine induced antibodies to HA from both IBV lineages. Notably, a trivalent vaccine containing HA from the B/
Vic lineage induced antibodies that cross-react with the B/Yam lineage.
1. Introduction
Influenza viruses cause 3–5 million cases of severe illness and
290,000–650,000 deaths per year worldwide during annual epidemics
(Lambert and Fauci, 2010). Co-circulating influenza A viruses (IAV) and
influenza B viruses (IBV) are responsible for this morbidity and mor-
tality. Similarly to IAV, IBV accumulates mutations in the gene en-
coding the surface glycoprotein hemagglutinin (HA) to avoid recogni-
tion by neutralizing antibodies induced by previous vaccinations or
infections, a process known as antigenic drift (Smith et al., 2004). Based
on genetic and antigenic variation of HA, two antigenically distinct
lineages of IBV are distinguished: B/Victoria/2/87-like (B/Vic) and B/
Yamagata/16/88-like (B/Yam) (Rota et al., 1990).
Currently used inactivated influenza vaccines aim at the induction
of virus-neutralizing antibodies directed to the variable head domain of
HA. These vaccines are trivalent (TIV) or quadrivalent (QIV) and con-
tain IBV antigens of one or both lineages, respectively. However, anti-
genic mismatches between circulating viruses and strains used for TIV
production frequently occur (Ambrose and Levin, 2012) and conse-
quently, TIV-induced antibodies neutralize IBV of the opposing lineage
inefficiently (Bodewes et al., 2011; van de Sandt et al., 2015). The
difficulty of predicting which IBV lineage will circulate in the next in-
fluenza season and poor cross-neutralization of IBV-specific antibodies
is the basis for the rationale to include IBV of both lineages in the
vaccine.
Virus neutralizing antibodies are mainly directed to antigenic sites
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in or around the receptor-binding site located in the head domain of
HA. In addition to these, antibodies with other immunologically im-
portant modes of action are induced. It has been demonstrated that
both natural infection and vaccination induce antibodies that mediate
antibody-dependent cellular cytotoxicity (ADCC), in addition to virus
neutralizing (VN) antibodies (de Vries et al., 2017a, b). Since these
ADCC mediating antibodies generally target the HA-stalk or conserved
regions in the HA-head, they are likely to display a high degree of cross-
reactivity and may be a correlate of cross-protective immunity
(Asthagiri Arunkumar et al., 2019; DiLillo et al., 2014). Therefore, the
HA-stalk is generally considered as an important target for future, more
broadly protective influenza vaccines.
Here, we determined whether vaccination with TIV or QIV induces
ADCC mediating antibodies directed to HA of IBV belonging to the two
different lineages. Furthermore, we analysed whether these antibodies
are specific for the HA-head or -stalk and whether these antibodies have
the capacity to cross-react with IBV of the opposing lineage.
2. Materials & methods
2.1. Ethics statement
The work described here has been carried out in accordance with
the code of ethics of the world medical association (declaration of
Helsinki). Informed consent was obtained from all participants.
Samples were obtained from clinical trials identified as NCT01946438
and NCT02258334 (clinicaltrials.gov).
2.2. Serum samples
Pre- and post-vaccination paired sera obtained from 41 healthy
study subjects (18 years up to 65, and 65 and older) were assessed for
the presence of ADCC mediating antibodies. Twenty-six subjects re-
ceived TIV (A/California/07/2009 (H1N1pdm09), A/Texas/50/2012
(H3N2) and B/Massachusetts/02/2012 [B/Yam-lineage]) and fifteen
subjects received QIV (A/California/07/2009, A/Texas/50/2012, B/
Massachusetts/02/2012 [B/Yam-lineage] and B/Brisbane/60/2008 [B/
Vic-lineage]). Vaccines used were split inactivated influenza vaccines
from the 2013–2014 and 2014–2015 season, containing 15 μg HA per
subtype. HI titers of these sera had been determined as an endpoint of
the clinical trials, but could not be unblinded at the time of preparation
of this manuscript. Consequently, serum samples were selected ob-
tained from individuals that displayed a wide range of HI antibody
responses to vaccination.
2.3. ADCC assay
ADCC assays were performed as described previously (de Vries
et al., 2017a, b). Briefly, either purified full-length baculovirus ex-
pressed recombinant HA protein or the HA1 subunit, were used. Full-
length HA from B/Brisbane/60/08 and HA1 from B/Malaysia/2506/04
were used as representative antigens from the B/Vic lineage, whereas
full-length HA from B/Yamanashi/166/98 and HA1 from B/Florida/4/
06 were used as B/Yam representatives. To test whether stalk-specific
antibodies were induced by vaccination, a chimeric full-length antigen
was used, consisting of the (irrelevant) head domain of an IAV of the H8
subtype (A/mallard/Sweden/24/02) and the stalk of IBV B/Yamagata/
16/88 (cH8/B). Microtiter plates (high-binding 96-wells flat bottom,
Fig. 1. Induction of ADCC mediating antibodies by vaccina-
tion with QIV or TIV. Presence of ADCC mediating antibodies
was determined by a flow cytometry-based assay performed with
paired serum samples obtained from 15 study subjects that re-
ceived QIV and 26 study subjects that received TIV. Sera were
tested against a full-length HA from B/Brisbane/60/08 (B/Vic
lineage) and B/Yamanashi/166/98 (B/Yam lineage), the HA1
subunits of B/Malaysia/2506/04 B/Vic lineage) and B/Florida/4/
06 (B/Yam lineage), and a chimeric HA consisting of the stalk of
B/Yamagata16/88 and the head domain of an IAV of the H8
subtype (cH8/B). (A) percentages obtained with pre- and post-
vaccination samples are plotted for comparison. (B) Response ra-
tios were calculated by dividing CD107a percentages in post-vac-
cination samples by CD107a percentages pre-vaccination. A
ratio> 1 means a positive response to vaccination.
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Immunolon) were coated overnight (200 ng/well). After coating, plates
were washed with PBS, blocked with 5 % bovine serum albumin (BSA)
and 100 μl volumes of diluted (1:160) serum sample was added. Ne-
gative and positive control serum sample were included in all experi-
ments. All sera were tested in duplicate, the complete assay was fully
reproduced twice. The continuous NK cell-line NK92.05-CD16 was used
as source of NK cells (Binyamin et al., 2008) and the presence of ADCC
mediating antibodies specific for the respective antigens was detected
by analysing these NK cells for the expression of degranulation marker
CD107a by flow cytometry. Live cells were gated on basis of forward
and sideward scatter and the percentage of CD107a positive cells was
acquired.
2.4. Statistical analysis
Statistical analyses were performed using GraphPad Prism.
CD107a+ percentages obtained with pre- and post-vaccination sera
were compared by performing a t-test on paired samples when the data
was normally distributed, or a Wilcoxon rank test on paired samples
when the data did not pass normality testing (Fig. 1A). Response ratios
were calculated by dividing CD107a percentages in post-vaccination
samples by CD107a percentages pre-vaccination. A ratio> 1 is in-
dicative of a positive response to vaccination (Fig. 1B)
3. Results
3.1. QIV induces ADCC mediating antibodies
The fifteen study subjects that received QIV developed significant
ADCC mediating antibody responses to the full-length HA from both
IBV lineages (B/Vic: p=0.0026, B/Yam: p=0.0054) (Fig. 1A and B).
Additionally, modest, but statistically significant ADCC mediating an-
tibody responses to the HA1 subunit of both lineages were detected (B/
Vic: p=0.0012, B/Yam: p= 0.0135), as well as responses to the HA-
stalk (cH8/B, p=0.0076) (Fig. 1A and B).
3.2. TIV induces cross-lineage ADCC mediating antibodies
The twenty-six study subjects that received TIV, containing IBV
from the B/Yam lineage (B/Massachusetts/02/2012), developed sig-
nificant ADCC mediating antibody responses to both the full-length HA
of the matching lineage (B/Yamanashi/166/98, p=0.0289) and the
full-length HA of the opposing lineage (B/Brisbane/60/08, p= 0.0079)
(Fig. 1A and B). Notably, although HA1-specific ADCC mediating an-
tibodies were detected at a low level, a statistically significant response
to HA1 of the matching (B/Flo/4/06, p < 0.0001) and opposing (B/
Mal/2506/04, p= 0.0012) lineage was also detected (Fig. 1A and B).
Additionally, an IBV HA-stalk-specific ADCC mediating antibody re-
sponse was observed after vaccination with TIV (p= 0.0010).
4. Discussion
Although hemagglutination inhibition (HI) and virus neutralizing
(VN) antibodies are regarded as the major correlates of protection from
(re-)infection with antigenically matching influenza virus strains, non-
neutralizing antibodies can also contribute to protective immunity. It
has previously been demonstrated that infection with IAV and IBV leads
to the induction of ADCC mediating antibodies (de Vries et al., 2017a,
b; Mesman et al., 2016), and vaccination of subjects with pre-existing
immunity to influenza viruses can increase the levels of ADCC med-
iating antibodies (de Vries et al., 2017a). It was also shown that primary
IBV infection led to the formation of cross-lineage ADCC mediating
antibodies, i.e. antibodies reactive with IBV from the opposing lineage
(de Vries et al., 2017b). Here, we show that administration of in-
activated influenza vaccines induces IBV-specific ADCC mediating an-
tibody responses. As expected, the use of QIV induced ADCC mediating
antibodies reactive with HA of viruses belonging to both the B/Vic and
B/Yam lineage. Notably, the use of TIV containing IBV of the B/Yam
lineage only, induced ADCC mediating antibodies to viruses of the
matching and the opposing lineage. This indicates that these antibodies
are cross-reactive and recognize conserved epitopes in both the head
and stalk domain.
Recent studies show that antibodies targeting the receptor-binding
domain located in the HA-head are not capable of mediating ADCC
(Asthagiri Arunkumar et al., 2019; DiLillo et al., 2014; Cox et al., 2016;
He et al., 2016; Leon et al., 2016). A stabilized immunological synapse
between target and effector cell is required for ADCC activity, fa-
cilitated by interactions between the receptor-binding domain of HA
and sialic acids on the one hand, and the Fc part of virus-specific im-
munoglobulin molecules and the FcγRIII on the other. Here, we show
that inactivated vaccines induce ADCC mediating antibodies specific for
both the HA1 and HA2 subunits. Notably, the HA1 subunit used in the
assays here is mainly the HA-head, but also contains part of the HA-
stalk. HA1-specific antibodies, likely reflecting HA-head-specific anti-
bodies, were only detected at low levels and were most likely specific
for epitopes located outside the receptor-binding domain. We therefore
confirmed that in the solid-phase ADCC assay and with the use of
NK92.05-CD16 cells, 2 points of contact between effector cells and HA
are still required for ADCC activity. Since epitopes located in these
regions are generally more conserved, this potentially explains the
cross-lineage reactivity of the vaccine induced ADCC antibodies.
In conclusion, we show that with the use of seasonal inactivated
influenza vaccines, IBV-specific ADCC mediating antibodies specific for
both the HA-head and HA-stalk were induced. In addition, TIV con-
taining HA derived from the B/Yam lineage induced antibodies cross-
reactive with the B/Vic lineage.
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